Search
Pretomanid
go.drugbank.com/drugs/DB05154ApprovedInvestigationalIt was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019. … Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesStreptococcus pneumoniae type 10A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB16714ApprovedInvestigational* serotype 10A individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197). … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.
Mixtures: Prevnar 20, Prevnar 20Synonyms: Streptococcus pneumoniae type 10A capsular polysaccharide diphtheria CRM197 protein conjugate antigenPerfluorooctane
go.drugbank.com/drugs/DB15997InvestigationalProducts: SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIALVilastobart
go.drugbank.com/drugs/DB19327InvestigationalVilastobart is under investigation in clinical trial NCT04896697 (Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors).
Synonyms: G1v7 CH2 D3, E117 (CH1 K120 (216) (120-217), hinge 1-, gamma1 heavy chain humanized (1-449) [VH (Homo sapiens IGHV1-69*08 (84.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT[8.8.12] (26-33.51-58.97-108)) (1-119) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, D12, L14,Human papillomavirus type 18 L1 capsid protein antigen
go.drugbank.com/drugs/DB10302ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces
Mixtures: GARDASIL 0.5 ML IM ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN FLAKON, CERVARIX 0,5 ML IM ENJEKSIYON ICIN SUSPANSIYON ICEREN FLAKON, 1 ADETNavtemadlin
go.drugbank.com/drugs/DB15299InvestigationalNavtemadlin (AMG-232) is under investigation in clinical trial NCT03041688 (MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia
Synonyms: {(3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[ (2S)-3 -methyl-1-(propan-2- ylsulfonyl)butan-2-yl]-2-oxopiperidin-3-yl}acetic acidLuliconazole
go.drugbank.com/drugs/DB08933ApprovedInvestigationalLuliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. … It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP2C19 InhibitorsJaktinib
go.drugbank.com/drugs/DB17545InvestigationalJaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating Patients With MDS With MF or MDS/MPN With MF.). … Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals.
Calcium cation
go.drugbank.com/drugs/DB14577InvestigationalMixtures: POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 100 ML (PVC TORBA) SETLI, POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 100 ML (PVC TORBA) SETSİZCyclin-dependent kinase 16
go.drugbank.com/bio_entities/BE0004077TargetHumansPlays a role in the regulation of insulin secretion in response to changes in blood glucose levels. Can phosphorylate CCNY at 'Ser-336' (in vitro)
Polypeptides: Cyclin-dependent kinase 16Synonyms: Cell division protein kinase 16